SCHEDULE 13D/A: Wittekind's Lunai Bioworks Stake Dips to 6.8%
Beneficial Ownership Amendment
William Anderson Wittekind's beneficial ownership in Lunai Bioworks Inc. decreased to 6.8% following the Issuer's recent share sale.
Summary
- William Anderson Wittekind's beneficial ownership in Lunai Bioworks Inc. has decreased from 7.8% to 6.8%.
- This change is primarily due to Lunai Bioworks Inc. selling 3,133,333 shares of Common Stock, as reported in a Form 8-K on November 25, 2025.
- Wittekind now beneficially owns an aggregate of 1,813,321 shares of Common Stock.
- His sole voting and dispositive power covers 560,665 shares, held directly and through entities/trusts where he is the sole manager/trustee.
- Shared voting and dispositive power covers 1,252,656 shares, including those held jointly with his spouse, Serhat Gumrukcu, and shares owned by Gumrukcu where Wittekind has power of attorney.
- A significant portion of shares (12,438,431) owned by Serhat Gumrukcu are subject to a writ of attachment related to a legal proceeding.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the decrease in beneficial ownership percentage for the reporting person and, more significantly, the disclosure of a substantial number of shares being subject to a writ of attachment due to legal proceedings involving a related party.
Negatives
- William Anderson Wittekind's beneficial ownership percentage in Lunai Bioworks Inc. decreased from 7.8% to 6.8%.
- 12,438,431 shares owned by Serhat Gumrukcu, Wittekind's spouse, over which Wittekind shares voting and dispositive power, are subject to a writ of attachment.
Risks
- The writ of attachment on 12,438,431 shares owned by Serhat Gumrukcu, Wittekind's spouse, in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123) poses a risk to the control and disposition of these shares.
Future Outlook
NA
Industry Context
This filing, a routine Schedule 13D amendment, primarily reflects a change in a significant shareholder's ownership percentage due to the company's share issuance. It does not provide specific insights into broader industry trends for the bioworks sector, beyond the general implication of a company raising capital.
Legal Proceedings
- 12,438,431 shares owned by Serhat Gumrukcu, Wittekind's spouse, are subject to a writ of attachment pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023.
- The writ of attachment is related to the case The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123).
Related Party Transactions
- William Anderson Wittekind shares voting and dispositive power over 1,243,844 shares owned by his spouse, Serhat Gumrukcu, through a power of attorney dated June 24, 2022.
- 8,813 shares are owned by Wittekind and Serhat Gumrukcu as joint tenants with a right of survivorship.
Stakeholder Impact
- Shareholders: The increase in outstanding shares due to the Issuer's sale could dilute existing shareholders. The writ of attachment on a large block of shares could introduce uncertainty regarding future control or disposition of those shares.
- Reporting Person (William Anderson Wittekind): His overall percentage ownership has decreased, and a significant portion of shares over which he has shared control are encumbered by a legal proceeding.
Key Dates
| Date | Description |
|---|---|
| 2018-01-12 | Date of Agreement and Plan of Merger between Issuer (then DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., Renovaro Biopharma, Inc. (then Enochian Biopharma Inc.), and Weird Science LLC. |
| 2022-06-24 | Date of power of attorney granting William Anderson Wittekind shared voting and dispositive power over shares owned by Serhat Gumrukcu. |
| 2023-10-27 | Date of United States District Court for the District of Vermont order subjecting 12,438,431 shares owned by Serhat Gumrukcu to a writ of attachment. |
| 2025-11-10 | Date as of which 23,432,391 shares were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 2025-11-14 | Date Issuer's Form 10-Q was filed with the Commission. |
| 2025-11-25 | Date of event requiring filing of this statement; Issuer filed a Form 8-K reporting the sale of 3,133,333 shares of Common Stock. |
| 2025-11-28 | Date of filing of this Amendment No. 23 to Schedule 13D. |
Recommendation
sellThe filing reveals a decrease in a significant insider's beneficial ownership percentage, which can be interpreted negatively by the market. More critically, the disclosure of a substantial block of shares (over which the insider has shared control) being subject to a writ of attachment due to ongoing legal proceedings against a related party introduces significant uncertainty and potential downside risk. This legal encumbrance could impact the liquidity and control of these shares, potentially signaling deeper issues or future selling pressure. Given these factors, a seasoned investor would likely consider reducing exposure.
Keywords
Lunai Bioworks Inc., William Anderson Wittekind, Schedule 13D, Beneficial Ownership, Common Stock, SEC Filing, Shareholder, Biotech, Corporate Governance, Writ of Attachment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.